Swissmedic: Warning from Brazil due to counterfeit medicinal products from Turkish wholesalers
The Brazilian health regulatory agency, ANVISA, warns of counterfeit medicinal products for which import was banned immediately.
This was announced by Swissmedic, who was informed directly by ANVISA on 23 September 2020.
The medicinal products were imported by the following Turkish wholesalers:
- Ankara Turkeli Ecza Deposu Ltd.Sti
- Poros Pharma
- Karen Ilac Ecza Deposu Ithalate Ihracat A.S.
These medicinal products are affected:
- Defibrotide (batch 0126)
- Soliris (batch 1000706, 1003254)
- Harvoni (batches 22VMYA12, 61264902)
A batch of Soliris was also obtained by a wholesaler from Switzerland and sold to Brazil.
Swissmedic points out once again that the responsibility for obtaining only medicinal products of high quality and ensuring that the source of supply is qualified accordingly lies with the holders of the authorization for distribution.
Source:
Meet the GMP Compliance Adviser
The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business.
The demo access is non-binding and ends automatically.
You may also be interested in the following articles:
